TAVR (transcatheter aortic valve replacement) is a minimally invasive heart procedure that replaces a diseased aortic valve without open-heart surgery. Instead of opening the chest, a doctor threads a new valve through a blood vessel, typically in the groin, and positions it inside the old valve. Most patients spend 3 to 5 days in the hospital and return to normal activities within about a month.
Why TAVR Is Performed
TAVR treats severe aortic stenosis, a condition where the aortic valve narrows and restricts blood flow out of the heart. A healthy aortic valve opens wide to let blood pass with each heartbeat. When it stiffens and calcifies over time, the heart has to pump harder and harder to push blood through the narrowed opening. This leads to symptoms like chest pain, shortness of breath, fatigue, and fainting.
Aortic stenosis is diagnosed using an echocardiogram that measures how fast blood squeezes through the valve and how much pressure builds up behind it. In very severe cases, the valve opening shrinks to less than 0.6 square centimeters, roughly the size of a pencil eraser, compared to the normal 3 to 4 square centimeters.
Who Qualifies for TAVR
TAVR was originally reserved for patients too frail for open-heart surgery, but guidelines have expanded significantly. The American College of Cardiology and American Heart Association now recommend TAVR as a safe and effective option for adults with symptomatic severe aortic stenosis regardless of surgical risk level. For patients over 80, TAVR is the preferred approach. For those between 65 and 80, either TAVR or traditional surgical valve replacement is reasonable, and the choice comes down to a conversation between you and your heart team. For adults under 65, surgical replacement is generally preferred unless other health conditions limit life expectancy.
That age-based guidance exists for an important reason: valve durability. A TAVR valve is made from biological tissue (usually cow or pig heart tissue), and it gradually wears out. Ten-year data shows that about 3% of TAVR valves develop severe structural deterioration, while roughly 11% show some degree of valve failure by the decade mark. For an 80-year-old, that timeline is rarely an issue. For a 55-year-old, it could mean needing a second procedure down the road.
How the Procedure Works
The most common approach, called transfemoral TAVR, enters through the femoral artery in the groin. Using ultrasound, the surgeon punctures the artery with a needle and threads a thin wire up through the blood vessel into the aorta. A large delivery sheath follows over that wire, creating a channel for the replacement valve.
Meanwhile, a temporary pacing wire is placed through a vein in the neck into the right side of the heart. This wire can control the heartbeat during critical moments of the procedure, briefly pacing the heart very fast to reduce its pumping force so the new valve can be positioned precisely.
The replacement valve is crimped down onto a catheter, small enough to fit inside the delivery sheath, and advanced up through the aorta. Using X-ray imaging and contrast dye injections, the team guides it into position inside the old, diseased valve. Once centered, the valve is deployed. Depending on the valve type, it either expands on its own (self-expanding) or is inflated with a small balloon (balloon-expandable). The new valve pushes the old valve leaflets aside and immediately begins working.
If the femoral artery is too small, too diseased, or too tortuous, alternative access points include the artery in the armpit area (transaxillary), the carotid artery in the neck, or in rare cases a direct approach through the chest wall or through the large vein next to the aorta (transcaval).
Two Types of TAVR Valves
Balloon-expandable valves are mounted on a balloon catheter. When the balloon inflates, the metal frame locks into place. Self-expanding valves are made of a shape-memory metal that expands on its own once released from its delivery sheath. Both types produce similar results overall, but there are meaningful differences in side effects.
Self-expanding valves are more likely to require a permanent pacemaker afterward, roughly twice as often as balloon-expandable valves. They also have higher rates of blood leaking around the edges of the new valve. Balloon-expandable valves, on the other hand, are more likely to cause a size mismatch where the valve opening is slightly too small relative to the patient’s body. Your heart team will choose the valve type based on your anatomy, the shape of your aortic root, and the specific characteristics of your valve disease.
Recovery After TAVR
Patients who have the standard transfemoral approach typically stay in the hospital for 3 to 4 days. Those who need an alternative access route through the armpit or chest usually stay 4 to 5 days. You’ll be monitored for heart rhythm changes, bleeding at the access site, and kidney function.
The first week at home comes with specific restrictions. You should avoid lifting anything over 10 pounds, which rules out groceries, laundry, and picking up children or pets. Keep the puncture site dry for a week, meaning showers are fine but no baths, pools, or hot tubs. For the full first month, hold off on running, biking, swimming, golf, tennis, and other sports until your 30-day follow-up visit.
After TAVR, most patients take low-dose aspirin indefinitely plus a second blood-thinning medication (clopidogrel) for 3 to 6 months. This combination helps prevent blood clots from forming on the new valve while tissue grows over the metal frame. If you’re already on a blood thinner for another condition like atrial fibrillation, your medication plan will be adjusted accordingly.
Risks and Complications
The most common significant complication is needing a permanent pacemaker. The replacement valve sits very close to the heart’s electrical wiring, and the pressure of the new frame can damage the conduction system. About 9.7% of TAVR patients require a pacemaker, though that rate has been declining as valve designs improve and implantation techniques become more precise.
Stroke is another concern. At five years, TAVR and traditional surgery show comparable stroke rates, though there is some signal that surgical replacement may carry a slight edge. Five-year mortality data from patients at low to intermediate surgical risk shows survival rates of about 70% for TAVR and 72% for surgical replacement. That small difference is driven largely by the older, sicker population that tends to receive TAVR rather than by the procedure itself. The study authors noted that long-term outcomes after TAVR are primarily shaped by a patient’s existing health conditions rather than by problems with the replacement valve.
Other possible complications include bleeding at the access site, kidney injury from the contrast dye used during imaging, and a small risk of the valve shifting out of position during or after deployment. Vascular complications at the groin entry point have decreased substantially as delivery systems have gotten smaller and imaging guidance has improved.
TAVR vs. Open-Heart Surgery
Traditional surgical aortic valve replacement (SAVR) requires opening the breastbone, stopping the heart, and placing the patient on a heart-lung bypass machine while the surgeon removes the old valve and sews in a new one. Recovery takes 6 to 8 weeks, and the procedure carries the physical toll of a major chest operation.
TAVR avoids all of that. There is no chest incision, no heart-lung machine, and no need to stop the heart. The trade-off is that TAVR leaves the old valve in place rather than removing it, and the long-term durability data, while encouraging at 10 years, doesn’t yet match the decades of follow-up available for surgical valves. For younger patients who may outlive their first valve, surgical replacement offers the option of a mechanical valve that can last a lifetime, though it requires lifelong blood thinners. For older patients or those with significant health risks, TAVR delivers similar outcomes with a much faster, less taxing recovery.